{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T04:59:49Z","timestamp":1769576389610,"version":"3.49.0"},"reference-count":87,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"vor","delay-in-days":1461,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["kisupplements.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International Supplements"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1016\/j.kisu.2017.10.005","type":"journal-article","created":{"date-parts":[[2017,12,29]],"date-time":"2017-12-29T04:21:40Z","timestamp":1514521300000},"page":"18-25","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"title":["Novel therapies for diabetic kidney disease"],"prefix":"10.1016","volume":"8","author":[{"given":"David Z.I.","family":"Cherney","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George L.","family":"Bakris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.kisu.2017.10.005_bib1","doi-asserted-by":"crossref","first-page":"694","DOI":"10.2337\/dc15-2322","article-title":"Long-term Benefits of Intensive Glucose Control for Preventing End-Stage Kidney Disease: ADVANCE-ON","volume":"39","author":"Wong","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1016\/j.kisu.2017.10.005_bib2","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1097\/MNH.0000000000000214","article-title":"New and old agents in the management of diabetic nephropathy","volume":"25","author":"Lytvyn","year":"2016","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1016\/j.kisu.2017.10.005_bib3","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1161\/CIRCULATIONAHA.116.021887","article-title":"Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes: cardiovascular and kidney effects, potential mechanisms and clinical applications","volume":"134","author":"Heerspink","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.kisu.2017.10.005_bib4","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1111\/dom.12307","article-title":"Efficacy and safety of empagliflozin for type 2 diabetes: a systematic review and meta-analysis","volume":"16","author":"Liakos","year":"2014","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.kisu.2017.10.005_bib5","doi-asserted-by":"crossref","first-page":"262","DOI":"10.7326\/0003-4819-159-4-201308200-00007","article-title":"Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis","volume":"159","author":"Vasilakou","year":"2013","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.kisu.2017.10.005_bib6","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/jdi.12214","article-title":"Renal sodium glucose cotransporter 2 inhibitors as a novel therapeutic approach to treatment of type 2 diabetes: clinical data and mechanism of action","volume":"5","author":"Fujita","year":"2014","journal-title":"J\u00a0Diabetes Investig"},{"key":"10.1016\/j.kisu.2017.10.005_bib7","article-title":"Empagliflozin in patients with type 2 diabetes mellitus (T2DM) and renal impairment (RI)","author":"Barnett","year":"2013","journal-title":"American Diabetes Association"},{"key":"10.1016\/j.kisu.2017.10.005_bib8","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1038\/ki.2013.356","article-title":"Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control","volume":"85","author":"Kohan","year":"2014","journal-title":"Kidney Int"},{"key":"10.1016\/j.kisu.2017.10.005_bib9","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1111\/dom.12348","article-title":"Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease","volume":"16","author":"Yale","year":"2014","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.kisu.2017.10.005_bib10","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kisu.2017.10.005_bib11","doi-asserted-by":"crossref","first-page":"F184","DOI":"10.1152\/ajprenal.00043.2017","article-title":"Urinary adenosine excretion in type 1 diabetes","volume":"313","author":"Rajasekeran","year":"2017","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.kisu.2017.10.005_bib12","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kisu.2017.10.005_bib13","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1111\/dom.12654","article-title":"Dapagliflozin reduces albuminuria in hypertensive diabetic patients using renin-angiotensin blockers","volume":"18","author":"Heerspink","year":"2016","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.kisu.2017.10.005_bib14","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1681\/ASN.2014070688","article-title":"Drug-induced reduction in albuminuria is associated with subsequent renoprotection: a meta-analysis","volume":"26","author":"Heerspink","year":"2015","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kisu.2017.10.005_bib15","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1515920","article-title":"Empagliflozin and progression of kidney disease in type 2 diabetes","volume":"375","author":"Wanner","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kisu.2017.10.005_bib16","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1002\/pds.932","article-title":"Antihypertensive drug therapy and the risk of lower extremity amputations in pharmacologically treated type 2 diabetes patients","volume":"13","author":"Erkens","year":"2004","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.kisu.2017.10.005_bib17","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1001\/jama.283.15.2013","article-title":"Diuretics vs alpha-blockers for treatment of hypertension: lessons from ALLHAT. Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial","volume":"283","author":"Lasagna","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.kisu.2017.10.005_bib18","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1001\/jama.283.15.1967","article-title":"Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT)","volume":"283","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.kisu.2017.10.005_bib19","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1001\/jama.288.23.2981","article-title":"Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT)","volume":"288","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.kisu.2017.10.005_bib20","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/S0140-6736(00)02527-7","article-title":"Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: intervention as a goal in hypertension treatment (INSIGHT)","volume":"356","author":"Brown","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.kisu.2017.10.005_bib21","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1161\/CIRCULATIONAHA.117.029190","volume":"136","author":"Kosiborod","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.kisu.2017.10.005_bib22","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1111\/dom.12889","article-title":"Novel oral glucose-lowering drugs are associated with lower risk of all-cause mortality, cardiovascular events and severe hypoglycaemia compared with insulin in patients with type 2 diabetes","volume":"19","author":"Nystr\u00f6m","year":"2017","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.kisu.2017.10.005_bib23","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1210\/jc.2016-3446","article-title":"All-cause mortality in patients with diabetes under treatment with dapagliflozin: a population-based, open-cohort study in the health improvementnetwork database","volume":"102","author":"Toulis","year":"2016","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.kisu.2017.10.005_bib24","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1177\/1479164114559852","article-title":"SGLT-2 inhibitors and cardiovascular risk: proposed pathways and review of ongoing outcome trials","volume":"12","author":"Inzucchi","year":"2015","journal-title":"Diab Vasc Dis Res"},{"key":"10.1016\/j.kisu.2017.10.005_bib25","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/nrneph.2013.272","article-title":"The gut-renal axis: do incretin-based agents confer renoprotection in diabetes?","volume":"10","author":"Muskiet","year":"2014","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.kisu.2017.10.005_bib26","article-title":"The potential and pitfalls of GLP-1 receptor agonists for renal protection in type 2 diabetes","volume":"43 Suppl 1","author":"Thomas","year":"2017","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.kisu.2017.10.005_bib27","doi-asserted-by":"crossref","first-page":"3055","DOI":"10.1210\/jc.2003-031403","article-title":"Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men","volume":"89","author":"Gutzwiller","year":"2004","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.kisu.2017.10.005_bib28","doi-asserted-by":"crossref","first-page":"132","DOI":"10.2337\/dc14-1958","article-title":"Liraglutide promotes natriuresis but does not increase circulating levels of atrial natriuretic peptide in hypertensive subjects with type 2 diabetes","volume":"38","author":"Lovshin","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1016\/j.kisu.2017.10.005_bib29","doi-asserted-by":"crossref","first-page":"E664","DOI":"10.1210\/jc.2012-3855","article-title":"Glucagon-like peptide-1 (GLP-1): effect on kidney hemodynamics and renin-angiotensin-aldosterone system in healthy men","volume":"98","author":"Skov","year":"2013","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.kisu.2017.10.005_bib30","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1007\/s00125-016-3938-z","article-title":"Acute renal effects of the GLP-1 receptor agonist exenatide in overweight type 2 diabetes patients: a randomised, double-blind, placebo-controlled trial","volume":"59","author":"Tonneijck","year":"2016","journal-title":"Diabetologia"},{"key":"10.1016\/j.kisu.2017.10.005_bib31","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s13098-015-0116-2","article-title":"Exenatide infusion decreases atrial natriuretic peptide levels by reducing cardiac filling pressures in type 2 diabetes patients with decompensated congestive heart failure","volume":"8","author":"Nathanson","year":"2016","journal-title":"Diabetol Metab Syndr"},{"key":"10.1016\/j.kisu.2017.10.005_bib32","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1210\/en.2013-1934","article-title":"GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody","volume":"155","author":"Pyke","year":"2014","journal-title":"Endocrinology"},{"key":"10.1016\/j.kisu.2017.10.005_bib33","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kisu.2017.10.005_bib34","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kisu.2017.10.005_bib35","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJMoa1307684","article-title":"Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus","volume":"369","author":"Scirica","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kisu.2017.10.005_bib36","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1056\/NEJMoa1501352","article-title":"Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes","volume":"373","author":"Green","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kisu.2017.10.005_bib37","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1056\/NEJMoa1305889","article-title":"Alogliptin after acute coronary syndrome in patients with type 2 diabetes","volume":"369","author":"White","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kisu.2017.10.005_bib38","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1056\/NEJMoa1509225","article-title":"Lixisenatide in patients with type 2 diabetes and acute coronary syndrome","volume":"373","author":"Pfeffer","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kisu.2017.10.005_bib39","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.kint.2016.06.012","article-title":"Stromal cell-derived factor-1 is upregulated by dipeptidyl peptidase-4 inhibition and has protective roles in progressive diabetic nephropathy","volume":"90","author":"Takashima","year":"2016","journal-title":"Kidney Int"},{"key":"10.1016\/j.kisu.2017.10.005_bib40","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.2337\/dc17-0061","article-title":"Dipeptidyl peptidase-4 inhibition stimulates distal tubular natriuresis and increases in circulating SDF-1alpha1-67 in patients with type 2 diabetes","volume":"40","author":"Lovshin","year":"2017","journal-title":"Diabetes Care"},{"key":"10.1016\/j.kisu.2017.10.005_bib41","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.2337\/dc16-1371","article-title":"Renal effects of DPP-4 inhibitor sitagliptin or GLP-1 receptor agonist liraglutide in overweight patients with type 2 diabetes: a 12-week, randomized, double-blind, placebo-controlled trial","volume":"39","author":"Tonneijck","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1016\/j.kisu.2017.10.005_bib42","doi-asserted-by":"crossref","first-page":"69","DOI":"10.2337\/dc16-0621","article-title":"Effect of saxagliptin on renal outcomes in the SAVOR-TIMI 53 trial","volume":"40","author":"Mosenzon","year":"2017","journal-title":"Diabetes Care"},{"key":"10.1016\/j.kisu.2017.10.005_bib43","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.2337\/dc16-1415","article-title":"Effect of sitagliptin on kidney function and respectivecardiovascular outcomes in type 2 diabetes: outcomes from TECOS","volume":"39","author":"Cornel","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1016\/j.kisu.2017.10.005_bib44","article-title":"Effects of linagliptin on glycemic control and albuminuria in type 2 diabetes\u2014the MARLINA-T2D\u2122 trial","author":"Groop","year":"2016","journal-title":"American Diabetes Association"},{"key":"10.1016\/j.kisu.2017.10.005_bib45","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1161\/01.CIR.0000032260.01569.64","article-title":"Increased activity of endogenous endothelin in patients with type II diabetes mellitus","volume":"106","author":"Cardillo","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.kisu.2017.10.005_bib46","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S0895-7061(98)00094-6","article-title":"Role of plasma and urinary endothelin-1 in early diabetic and hypertensive nephropathy","volume":"11","author":"De Mattia","year":"1998","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.kisu.2017.10.005_bib47","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1016\/S0026-0495(98)90314-6","article-title":"Urinary endothelin in adolescents and young adults with insulin-dependent diabetes mellitus: relation to urinary albumin, blood pressure, and other factors","volume":"47","author":"Peppa-Patrikiou","year":"1998","journal-title":"Metabolism"},{"key":"10.1016\/j.kisu.2017.10.005_bib48","doi-asserted-by":"crossref","first-page":"571","DOI":"10.3109\/00365519609088813","article-title":"The correlation of plasma and urine endothelin-1 with the severity of nephropathy in Chinese patients with type 2 diabetes","volume":"56","author":"Shin","year":"1996","journal-title":"Scand J Clin Lab Invest"},{"key":"10.1016\/j.kisu.2017.10.005_bib49","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.2337\/diacare.21.6.1004","article-title":"Carotid atherosclerosis in adolescents and young adults with IDDM. Relation to urinary endothelin, albumin, free cortisol, and other factors","volume":"21","author":"Peppa-Patrikiou","year":"1998","journal-title":"Diabetes Care"},{"key":"10.1016\/j.kisu.2017.10.005_bib50","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1038\/ki.1994.284","article-title":"Effects of endothelin-1 on renal function in humans: implications for physiology and pathophysiology","volume":"46","author":"Rabelink","year":"1994","journal-title":"Kidney Int"},{"key":"10.1016\/j.kisu.2017.10.005_bib51","doi-asserted-by":"crossref","first-page":"H2743","DOI":"10.1152\/ajpheart.91487.2007","article-title":"Effect of chronic and selective endothelin receptor antagonism on microvascular function in type 2 diabetes","volume":"294","author":"Sachidanandam","year":"2008","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.kisu.2017.10.005_bib52","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1056\/NEJM199803193381202","article-title":"The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. Bosentan hypertension investigators","volume":"338","author":"Krum","year":"1998","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kisu.2017.10.005_bib53","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1681\/ASN.2009060593","article-title":"Avosentan for overt diabetic nephropathy","volume":"21","author":"Mann","year":"2010","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kisu.2017.10.005_bib54","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1161\/HYPERTENSIONAHA.108.113068","article-title":"Efficacy and safety of atrasentan in patients with cardiovascular risk and early atherosclerosis","volume":"52","author":"Raichlin","year":"2008","journal-title":"Hypertension"},{"key":"10.1016\/j.kisu.2017.10.005_bib55","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1681\/ASN.2008050482","article-title":"Avosentan reduces albumin excretion in diabetics with macroalbuminuria","volume":"20","author":"Wenzel","year":"2009","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kisu.2017.10.005_bib56","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1038\/clpt.2009.15","article-title":"Dose-dependent acute and sustained renal effects of the endothelin receptor antagonist avosentan in healthy subjects","volume":"85","author":"Smolander","year":"2009","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.kisu.2017.10.005_bib57","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1111\/bcp.12064","article-title":"Endothelin antagonists for diabetic and non-diabetic chronic kidney disease","volume":"76","author":"Kohan","year":"2013","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.kisu.2017.10.005_bib58","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.2215\/CJN.00570115","article-title":"Predictors of atrasentan-associated fluid retention and change in albuminuria in patients with diabetic nephropathy","volume":"10","author":"Kohan","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kisu.2017.10.005_bib59","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.lfs.2012.01.011","article-title":"Clinical efficacy of the selective endothelin A receptor antagonist, atrasentan, in patients with diabetes and chronic kidney disease (CKD)","volume":"91","author":"Andress","year":"2012","journal-title":"Life Sci"},{"key":"10.1016\/j.kisu.2017.10.005_bib60","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1681\/ASN.2013080830","article-title":"The endothelin antagonist atrasentan lowers residual albuminuria in patients with type 2 diabetic nephropathy","volume":"25","author":"de Zeeuw","year":"2014","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kisu.2017.10.005_bib61","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1681\/ASN.2010080869","article-title":"Addition of atrasentan to renin-angiotensin system blockade reduces albuminuria in diabetic nephropathy","volume":"22","author":"Kohan","year":"2011","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kisu.2017.10.005_bib62","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1111\/dom.12864","article-title":"The effects of atrasentan on urinary metabolites in patients with type 2 diabetes and nephropathy","volume":"19","author":"Pena","year":"2017","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.kisu.2017.10.005_bib63","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1111\/j.1751-7176.2012.00704.x","article-title":"Catheter-based renal sympathetic denervation improves central hemodynamics and arterial stiffness: a pilot study","volume":"14","author":"Mortensen","year":"2012","journal-title":"J\u00a0Clin Hypertens (Greenwich)"},{"key":"10.1016\/j.kisu.2017.10.005_bib64","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1161\/HYPERTENSIONAHA.111.00194","article-title":"Substantial reduction in single sympathetic nerve firing after renal denervation in patients with resistant hypertension","volume":"61","author":"Hering","year":"2013","journal-title":"Hypertension"},{"key":"10.1016\/j.kisu.2017.10.005_bib65","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1053\/j.ajkd.2007.10.040","article-title":"Change in proteinuria after adding aldosterone blockers to ACE inhibitors or angiotensin receptor blockers in CKD: a systematic review","volume":"51","author":"Bomback","year":"2008","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kisu.2017.10.005_bib66","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1056\/NEJM200109203451215","article-title":"Spironolactone in addition to ACE inhibition to reduce proteinuria in patients with chronic renal disease","volume":"345","author":"Chrysostomou","year":"2001","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kisu.2017.10.005_bib67","doi-asserted-by":"crossref","first-page":"940","DOI":"10.2215\/CJN.00240106","article-title":"Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes","volume":"1","author":"Epstein","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kisu.2017.10.005_bib68","doi-asserted-by":"crossref","first-page":"2829","DOI":"10.1111\/j.1523-1755.2005.00756.x","article-title":"Beneficial impact of spironolactone in diabetic nephropathy","volume":"68","author":"Schjoedt","year":"2005","journal-title":"Kidney Int"},{"key":"10.1016\/j.kisu.2017.10.005_bib69","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.2337\/diacare.28.9.2106","article-title":"Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: a randomized, double-masked, cross-over study","volume":"28","author":"Rossing","year":"2005","journal-title":"Diabetes Care"},{"key":"10.1016\/j.kisu.2017.10.005_bib70","first-page":"CD007004","article-title":"Aldosterone antagonists for preventing the progression of chronic kidney disease","volume":"4","author":"Bolignano","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.kisu.2017.10.005_bib71","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1093\/eurheartj\/eht187","article-title":"Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial","volume":"34","author":"Pitt","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.kisu.2017.10.005_bib72","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1001\/jama.2015.10081","article-title":"Effect of finerenone on albuminuria in patients with diabetic nephropathy: a randomized clinical trial","volume":"314","author":"Bakris","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.kisu.2017.10.005_bib73","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1161\/HYPERTENSIONAHA.111.00540","article-title":"Catheter-based renal nerve ablation and centrally generated sympathetic activity in difficult-to-control hypertensive patients: prospective case series","volume":"61","author":"Mahfoud","year":"2013","journal-title":"Hypertension"},{"key":"10.1016\/j.kisu.2017.10.005_bib74","doi-asserted-by":"crossref","first-page":"e13","DOI":"10.1161\/HYPERTENSIONAHA.111.00492","article-title":"Blood pressure and sympathetic nervous system response to renal denervation","volume":"61","author":"Schlaich","year":"2013","journal-title":"Hypertension"},{"key":"10.1016\/j.kisu.2017.10.005_bib75","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.numecd.2012.09.004","article-title":"Renal denervation in cardiometabolic disease: concepts, achievements and perspectives","volume":"23","author":"Grassi","year":"2013","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"10.1016\/j.kisu.2017.10.005_bib76","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1080\/13543784.2016.1196184","article-title":"Targeting inflammation in diabetic kidney disease: early clinical trials","volume":"25","author":"Perez-Gomez","year":"2016","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.kisu.2017.10.005_bib77","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.jcjd.2014.10.013","article-title":"Uric acid as a biomarker and a therapeutic target in diabetes","volume":"39","author":"Lytvyn","year":"2015","journal-title":"Can J Diabetes"},{"key":"10.1016\/j.kisu.2017.10.005_bib78","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.jpeds.2012.12.078","article-title":"Uric acid and the origins of hypertension","volume":"162","author":"Feig","year":"2013","journal-title":"J\u00a0Pediatr"},{"key":"10.1016\/j.kisu.2017.10.005_bib79","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1053\/j.ajkd.2012.07.021","article-title":"Uric acid as a target of therapy in CKD","volume":"61","author":"Jalal","year":"2013","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kisu.2017.10.005_bib80","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1093\/ndt\/gft029","article-title":"Uric acid and chronic kidney disease: which is chasing which?","volume":"28","author":"Johnson","year":"2013","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kisu.2017.10.005_bib81","doi-asserted-by":"crossref","first-page":"611","DOI":"10.2337\/dc15-2345","article-title":"Association between plasma uric acid levels and cardiorenal function in adolescents with type 1 diabetes","volume":"39","author":"Lytvyn","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1016\/j.kisu.2017.10.005_bib82","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1111\/dme.13051","article-title":"Plasma uric acid effects on glomerular haemodynamic profile of patients with uncomplicated type 1 diabetes mellitus","volume":"33","author":"Lytvyn","year":"2016","journal-title":"Diabet Med"},{"key":"10.1016\/j.kisu.2017.10.005_bib83","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1007\/s11892-013-0381-0","article-title":"Uric acid lowering to prevent kidney function loss in diabetes: the Preventing Early Renal Function Loss (PERL) allopurinol study","volume":"13","author":"Maahs","year":"2013","journal-title":"Curr Diab Rep"},{"key":"10.1016\/j.kisu.2017.10.005_bib84","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1111\/dom.12127","article-title":"Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes","volume":"15","author":"Lambers Heerspink","year":"2013","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.kisu.2017.10.005_bib85","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1161\/CIRCULATIONAHA.113.005081","article-title":"Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus","volume":"129","author":"Cherney","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.kisu.2017.10.005_bib86","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/S2213-8587(16)30263-7","article-title":"GLP-1 receptor agonists and SGLT2 inhibitors:\u00a0a couple at last?","volume":"4","author":"Nauck","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.kisu.2017.10.005_bib87","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/S2213-8587(16)30267-4","volume":"4","author":"Fr\u00edas","year":"2016","journal-title":"Lancet Diabetes Endocrinol"}],"container-title":["Kidney International Supplements"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S215717161730062X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S215717161730062X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,30]],"date-time":"2024-06-30T05:17:34Z","timestamp":1719724654000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S215717161730062X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":87,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["S215717161730062X"],"URL":"https:\/\/doi.org\/10.1016\/j.kisu.2017.10.005","relation":{},"ISSN":["2157-1716"],"issn-type":[{"value":"2157-1716","type":"print"}],"subject":[],"published":{"date-parts":[[2018,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel therapies for diabetic kidney disease","name":"articletitle","label":"Article Title"},{"value":"Kidney International Supplements","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.kisu.2017.10.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 International Society of Nephrology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}